NCT/Study#
NA /
CDA5050/0006
Phase 1 Open-Label Study With A Novel Triple Mechanism Of Action IP In Combination With Pembrolizumab For Advanced Malignancies.
DISEASE GROUP:
Phase 1 Clinical Trials
current phase:
Phase I
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
